NASDAQ:CVAC CureVac (CVAC) Stock Price, News & Analysis $5.38 -0.01 (-0.19%) Closing price 04:00 PM EasternExtended Trading$5.42 +0.04 (+0.65%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About CureVac Stock (NASDAQ:CVAC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CureVac alerts:Sign Up Key Stats Today's Range$5.38▼$5.4150-Day Range$5.34▼$5.4852-Week Range$2.37▼$5.72Volume351,007 shsAverage Volume430,007 shsMarket Capitalization$1.21 billionP/E Ratio5.60Dividend YieldN/APrice Target$6.83Consensus RatingHold Company Overview CureVac N.V. is a clinical-stage biopharmaceutical company that specializes in the research, development and commercialization of messenger RNA (mRNA)-based medicines and vaccines. Leveraging its proprietary mRNA platform, the company seeks to harness the body’s natural protein production processes to address a range of diseases, with particular emphasis on prophylactic vaccines for infectious diseases as well as therapeutic candidates in oncology. CureVac’s technology is designed to deliver optimized mRNA sequences for in vivo expression, aiming to improve stability, translational efficiency and immunogenicity compared with conventional approaches. Founded in 2000 and headquartered in Tübingen, Germany, CureVac has built a pipeline spanning early- to late-stage clinical programs. Its RNActive® platform underpins several vaccine candidates, including those targeting seasonal influenza, rabies and other viral pathogens. In oncology, the company is advancing individualized neoantigen vaccines and combination immunotherapies designed to stimulate targeted anti-tumor immune responses. Over the years, CureVac has entered collaborations with pharmaceutical partners to co-develop next-generation mRNA products, most notably a strategic partnership announced in 2021 focused on seasonal influenza vaccines. CureVac maintains research facilities in Germany and actively engages with the global scientific community through alliances and academic collaborations. The company also operates a presence in the United States to support clinical development and regulatory interactions. Leadership is led by Franz-Werner Haas, who has served as Chief Executive Officer since 2018, guiding CureVac’s transition from pioneering research to commercialization readiness. Supported by an interdisciplinary team of biologists, chemists and clinicians, the company continues to expand its platform capabilities and explore new indications for mRNA therapeutics.AI Generated. May Contain Errors. Read More CureVac Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreCVAC MarketRank™: CureVac scored higher than 71% of companies evaluated by MarketBeat, and ranked 298th out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingHold Consensus RatingCureVac has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.Upside PotentialCureVac has a consensus price target of $6.83, representing about 27.0% upside from its current price of $5.38.Amount of Analyst CoverageCureVac has only been the subject of 1 research reports in the past 90 days.Read more about CureVac's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CureVac are expected to decrease in the coming year, from $0.72 to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CureVac is 5.60, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 82.64.Price to Earnings Ratio vs. SectorThe P/E ratio of CureVac is 5.60, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 29.66.Price to Book Value per Share RatioCureVac has a P/B Ratio of 1.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CureVac's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.27% of the float of CureVac has been sold short.Short Interest Ratio / Days to CoverCureVac has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CureVac has recently increased by 2.54%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCureVac does not currently pay a dividend.Dividend GrowthCureVac does not have a long track record of dividend growth. Sustainability and ESG4.9 / 5Environmental Score-2.22 Percentage of Shares Shorted1.27% of the float of CureVac has been sold short.Short Interest Ratio / Days to CoverCureVac has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CureVac has recently increased by 2.54%, indicating that investor sentiment is decreasing. News and Social Media0.0 / 5News SentimentN/A Search InterestOnly 1 people have searched for CVAC on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CureVac insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.15% of the stock of CureVac is held by insiders.Percentage Held by InstitutionsOnly 17.26% of the stock of CureVac is held by institutions.Read more about CureVac's insider trading history. Receive CVAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CVAC Stock News HeadlinesCureVac: The Hidden Value Of The mRNA WalletOctober 1, 2025 | seekingalpha.comCureVac (NasdaqGM:CVAC) Valuation in Focus After Recent Share Price MovementsSeptember 13, 2025 | finance.yahoo.comBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's preparing for a "mind blowing" new launch that could see Tesla move away from electric cars... and into a new market.October 23 at 2:00 AM | Altimetry (Ad)CureVac’s Strategic Moves and Financial Highlights in 2025August 26, 2025 | msn.comCureVac sees cash runway into 2028August 16, 2025 | msn.comCureVac reports Q2 revenue EUR 1.2M vs. EUR 14.4M last yearAugust 16, 2025 | msn.comCureVac Reports Financial Losses in Mid-2025August 16, 2025 | msn.comCureVac settles patent dispute litigation with Pfizer and BioNTechAugust 7, 2025 | reuters.comSee More Headlines CVAC Stock Analysis - Frequently Asked Questions How have CVAC shares performed this year? CureVac's stock was trading at $3.41 on January 1st, 2025. Since then, CVAC shares have increased by 57.8% and is now trading at $5.38. How were CureVac's earnings last quarter? CureVac N.V. (NASDAQ:CVAC) announced its quarterly earnings data on Thursday, August, 21st. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.15) by $0.15. The business earned $1.41 million during the quarter, compared to analysts' expectations of $4.27 million. CureVac had a net margin of 38.21% and a trailing twelve-month return on equity of 29.57%. When did CureVac IPO? CureVac (CVAC) raised $200 million in an initial public offering (IPO) on Friday, August 14th 2020. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse served as the underwriters for the IPO and Berenberg and Kempen were co-managers. Who are CureVac's major shareholders? CureVac's top institutional shareholders include Green Alpha Advisors LLC (0.01%). How do I buy shares of CureVac? Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CureVac own? Based on aggregate information from My MarketBeat watchlists, some other companies that CureVac investors own include NVIDIA (NVDA), PayPal (PYPL), Tesla (TSLA), NIO (NIO), Advanced Micro Devices (AMD), Meta Platforms (META) and Moderna (MRNA). Company Calendar Last Earnings8/21/2025Today10/23/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CVAC CIK1809122 Webwww.curevac.com Phone49-70-71988-30Fax49-7071-9883Employees880Year Founded2000Price Target and Rating Average Price Target for CureVac$6.83 High Price Target$10.00 Low Price Target$5.00 Potential Upside/Downside+26.7%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)$0.96 Trailing P/E Ratio5.62 Forward P/E Ratio7.49 P/E GrowthN/ANet Income$175.50 million Net Margins38.21% Pretax Margin42.22% Return on Equity29.57% Return on Assets25.41% Debt Debt-to-Equity Ratio0.05 Current Ratio6.17 Quick Ratio6.16 Sales & Book Value Annual Sales$579.18 million Price / Sales2.09 Cash Flow$0.88 per share Price / Cash Flow6.15 Book Value$3.36 per share Price / Book1.61Miscellaneous Outstanding Shares224,340,000Free Float219,515,000Market Cap$1.21 billion OptionableOptionable Beta2.51 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:CVAC) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | Sponsored7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all...American Alternative | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.